Alibaba Health

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00241)

APPOINTMENT OF EXECUTIVE DIRECTOR; CHANGE OF CHAIRMAN, CHIEF EXECUTIVE OFFICER AND AUTHORIZED REPRESENTATIVE; AND CHANGE IN COMPOSITION OF NOMINATION COMMITTEE

The board (the "**Board**") of directors (the "**Directors**") of Alibaba Health Information Technology Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that, with effect from the close of business on September 11, 2026:

(i) Mr. Yu Yong (余涌) ("**Mr. Yu**") has been appointed as an executive Director, chairman of the Board (the "**Chairman**"), chief executive officer (the "**Chief Executive Officer**"), the chairman of the nomination committee (the "**Nomination Committee**") of the Company and an authorized representative of the Company (the "**Authorized Representative**") under Rule 3.05 of the Rules Governing the Listing of Securities ("**Listing Rules**") on The Stock Exchange of Hong Kong Limited ("**Stock Exchange**"); and

(ii) Mr. Shen Difan ("**Mr. Shen**") has tendered his resignation as the Chairman, the Chief Executive Officer, the chairman of the Nomination Committee and an Authorized Representative.

APPOINTMENT OF EXECUTIVE DIRECTOR, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE OFFICER AND THE CHAIRMAN OF THE NOMINATION COMMITTEE

The Board is pleased to announce that Mr. Yu has been appointed as an executive Director, the Chairman, the Chief Executive Officer, the chairman of the Nomination Committee, and an Authorized Representative with effect from the close of business on September 11, 2026.

The biography of Mr. Yu is set out below:

Mr. Yu, aged 50, joined Alibaba Group Holding Limited ("**Alibaba Holding**") and its subsidiaries (collectively, "**Alibaba Group**") in March 2005. He served as the executive director, general manager and legal representative of a number of subsidiaries under Alibaba Group. Mr. Yu possesses more than 20 years of experience in consumer and e-commerce industries. Mr. Yu also has extensive experience in merchant operations and supply chain transformation. Over his tenure at Alibaba Group, he has held leadership roles across core B2B businesses, including Alibaba.com and 1688.com. From February 2022 to September 2026, Mr. Yu served as the chief executive officer and president of 1688.com, a business-to-business wholesale platform of Alibaba Group. In this capacity, he has spearheaded strategic initiatives including 1688 Select and AI-to-B Supply Chain, driving the platform's transformation from a wholesale marketplace into an industrial supply chain platform. Prior to joining Alibaba Group, Mr. Yu had over 10 years of experience in the logistics industry.

Mr. Yu obtained a bachelor's degree in international trade from Ningbo University in the PRC in July 1994. Mr. Yu was accredited as a Senior Economist (Professor-level) in November 2018, being among the first batch to have obtained such accreditation in Zhejiang Province. He was also accredited as a Category B Talent by the Hangzhou Municipal Government in June 2024, and is a national-level leading talent in science and technology. Mr. Yu has also served as a supervisor for master's degrees at the School of Economics in Zhejiang University from March 2022. Mr. Yu has also served as a supervisor for master's degrees at the International Business School in Ningbo University since June 2025.

Save as disclosed herein and as at the date of this announcement, Mr. Yu (i) is not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) does not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years preceding the date of this announcement, or any other position within the Company or other members of the Group.

Mr. Yu has entered into an appointment letter as an executive Director with the Company for a term of one year commencing from September 11, 2026, which is renewable for a one-year period upon expiry of each term. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the provisions of the bye-laws of the Company and the Listing Rules. There is no separate service contract in relation to Mr. Yu's appointment as the Chairman, the Chief Executive Officer, the chairman of the Nomination Committee and an Authorized Representative. The remuneration for Mr. Yu's position as an executive Director, the Chairman, the Chief Executive Officer, the chairman of the Nomination Committee, an Authorized Representative and any other positions (if any) will be determined by the

Company based on the recommendation from the remuneration committee of the Company (if appropriate) with reference to the Company's remuneration policy and taken into account, among other factors, his qualification and experience, responsibilities undertaken, contribution to the Company and the prevailing market level of remuneration of similar positions. The Company will disclose such details as soon as practicable.

Save as disclosed herein, Mr. Yu has confirmed that there is no other information required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter relating to his appointment that needs to be brought to the attention of the shareholders of the Company.

The Board would like to congratulate Mr. Yu on his new appointment.

RESIGNATION OF CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE OFFICER, THE CHAIRMAN OF THE NOMINATION COMMITTEE AND AN AUTHORIZED REPRESENTATIVE

The Board further announces that Mr. Shen has tendered his resignation as the Chairman of the Board, the Chief Executive Officer, the chairman of the Nomination Committee and an Authorized Representative with effect from the close of business on September 11, 2026. Mr. Shen remains as an executive Director. Mr. Shen will increase his involvement in Alibaba Group's AI business, focusing on the development and advancement of industry-specific AI solutions and applications for the healthcare sector. Mr. Shen will continue to lead the Group's Hydrion and digital tracking business.

Mr. Shen has confirmed that he has no disagreement with the Board and there are no circumstances related to his resignation as the Chairman, the Chief Executive Officer, the chairman of the Nomination Committee and an Authorized Representative which need to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Shen for his valuable contributions during his tenure of office as the Chairman, the Chief Executive Officer, the chairman of the Nomination Committee and an Authorized Representative.

OTHER INFORMATION

Code provision C.2.1 of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules stipulates that the roles of chairman and chief executive should be separate and should not be performed by the same individual. Accordingly, the appointment of Mr. Yu as the Chief Executive Officer and the Chairman deviates from the relevant code provision. The Board believes that the current leadership structure provides the Company with strong and consistent leadership, and a unified voice in articulating the Company's business and strategy. At the same time, the Board maintains an active oversight framework with robust checks and balances to protect the interests of the Company and its shareholders. The Board will continue to assess the effectiveness of the Company's leadership structure while fulfilling its fiduciary duty to determine the governance structure that best serves the interests of shareholders.

For and on behalf of the Board
Alibaba Health Information Technology Limited
Yu Yong
Chairman and Chief Executive Officer

Hong Kong, September 11, 2026

As at the date of this announcement, the Board comprises Mr. Yu Yong, Mr. Shen Difan and Ms. Sheng Mengyue as the executive Directors; Ms. Huang Jiaojiao as the non-executive Director; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.